Full-Time

Global Ethics & Compliance Business Partner

Oncology

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Global biopharmaceutical company focused on R&D

Compensation Overview

$174.5k - $274.2k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Boston, MA, USA

This position is currently classified as 'hybrid' in accordance with Takeda's Hybrid and Remote Work policy.

Category
Risk & Compliance
Legal & Compliance
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Takeda referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Minimum of 8 years of Ethics & Compliance related experience; preferably with at least 5 years as part of medical device or pharmaceutical industry
  • Strong understanding of pharma market
  • Demonstrated knowledge of key laws, regulations and industry best practice standards
  • Experience in aligning potential, present and future compliance risks related to the business, including risk identification, controls & risk mitigation of potential non-compliance
  • Deep insights into ethical business decision making and very strong stakeholder-facing interactions and leadership by influence abilities.
Responsibilities
  • Provide proactive business engagement and support to and ensure implementation of required elements of Takeda’s Ethics & Compliance program within Global Oncology Medical, Global Oncology Patient Value and Access, Global Oncology Products & Pipeline Strategy, and serve as principal OBU E&C liaison to commercial leadership teams within Japan and EUCAN countries who report into GOBU.
  • Act as a catalyst in shaping the organizational mindset around a Values based culture to firmly embed ethical decision-making principles in GOBU.
  • Evaluate and advise the GOBU global teams in compliance risks related to their activities, evaluate and escalate issues as needed.
  • Ensure alignment and support to ex-US OBU businesses (i.e., EUCAN and Japan OBU), including closer liaison with LOC E&C colleagues. Coordinate quarterly meetings with Japan and EUCAN OBU E&C to help identify trends and issues spanning across GOBU.
  • Increase business acumen by obtaining therapeutic and product knowledge to support current and pipeline products.
  • Provide input into global E&C Policies/SOPs and training and engage in other initiatives or programs as relevant. Interface with other E&C teams to ensure appropriate level of GOBU support.
  • Support the management and creation of OBU E&C specific SOPs and related trainings that are relevant to the global functions.
Desired Qualifications
  • While specific ethics & compliance business partner experience is strongly preferred, substantive experience gained in role(s) where the handling of compliance-related matters form part of such role(s) would also be considered.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene is worth up to $770 million.
  • The company is expanding its market presence in emerging Asian economies.
  • Takeda's focus on personalized medicine aligns with industry trends.

What critics are saying

  • Antitrust litigation over Amitiza could harm Takeda's reputation and finances.
  • A data breach incident poses significant cybersecurity and legal risks.
  • The telehealth market's rapid changes may affect Takeda's investment in American Well.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations.
  • Takeda has a robust pipeline with 11 NMEs and aims for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

ETF Daily News
May 11th, 2025
Tudor Investment Corp ET AL Decreases Stock Holdings in American Well Co. (NYSE:AMWL)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in American Well in the fourth quarter worth about $564,000.

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.